Top

Published in:

Open Access 01-08-2010 | Research article

Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro

Authors: Fiona Lanigan, Gabriela Gremel, Rowena Hughes, Donal J Brennan, Finian Martin, Karin Jirström, William M Gallagher

Published in: Breast Cancer Research | Issue 4/2010

Abstract

Introduction

The homeobox-containing transcription factor muscle segment homeobox 2 (Msx2) plays an important role in mammary gland development. However, the clinical implications of Msx2 expression in breast cancer are unclear. The aims of this study were to investigate the potential clinical value of Msx2 as a breast cancer biomarker and to clarify its functional role in vitro.

Methods

Msx2 gene expression was first examined in a well-validated breast cancer transcriptomic dataset of 295 patients. Msx2 protein expression was then evaluated by immunohistochemistry in a tissue microarray (TMA) containing 281 invasive breast tumours. Finally, to assess the functional role of Msx2 in vitro, Msx2 was ectopically expressed in a highly invasive breast tumour cell line (MDA-MB-231) and an immortalised breast cell line (MCF10a), and these cell lines were examined for changes in growth rate, cell death and cell signalling.

Results

Examination of Msx2 mRNA expression in a breast cancer transcriptomic dataset demonstrated that increased levels of Msx2 were associated with good prognosis (P = 0.011). Evaluation of Msx2 protein expression on a TMA revealed that Msx2 was detectable in both tumour cell nuclei and cytoplasm. Cytoplasmic Msx2 expression was associated with low grade tumours (P = 0.012) and Ki67 negativity (P = 0.018). Nuclear Msx2 correlated with low-grade tumours (P = 0.015), estrogen receptor positivity (P = 0.038), low Ki67 (P = 0.005) and high cyclin D1 expression (P = 0.037). Increased cytoplasmic Msx2 expression was associated with a prolonged breast cancer-specific survival (P = 0.049), recurrence-free survival (P = 0.029) and overall survival (P = 0.019). Ectopic expression of Msx2 in breast cell lines resulted in radically decreased cell viability mediated by induction of cell death via apoptosis. Further analysis of Msx2-expressing cells revealed increased levels of p21 and phosphorylated extracellular signal-regulated kinase (ERK) and decreased levels of Survivin and the 'split ends' (SPEN) protein family member RBM15.

Conclusions

We conclude that increased Msx2 expression results in improved outcome for breast cancer patients, possibly by increasing the likelihood of tumour cell death by apoptosis.

Available only for authorised users

Chen YH, Ishii M, Sun J, Sucov HM, Maxson RE: Msx1 and Msx2 regulate survival of secondary heart field precursors and post-migratory proliferation of cardiac neural crest in the outflow tract. Dev Biol. 2007, 308: 421-437. 10.1016/j.ydbio.2007.05.037.CrossRefPubMed

Lallemand Y, Bensoussan V, Cloment CS, Robert B: Msx genes are important apoptosis effectors downstream of the Shh/Gli3 pathway in the limb. Dev Biol. 2009, 331: 189-198. 10.1016/j.ydbio.2009.04.038.CrossRefPubMed

Phippard DJ, Weber-Hall SJ, Sharpe PT, Naylor MS, Jayatalake H, Maas R, Woo I, Roberts-Clark D, Francis-West PH, Liu YH, Maxson R, Hill RE, Dale TC: Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development. Development. 1996, 122: 2729-2737.PubMed

Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, Maeda T, Takano Y, Uchiyama M, Heaney S, Peters H, Tang Z, Maxson R, Maas R: Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet. 2000, 24: 391-395. 10.1038/74231.CrossRefPubMed

Takahashi K, Nuckolls GH, Tanaka O, Semba I, Takahashi I, Dashner R, Shum L, Slavkin HC: Adenovirus-mediated ectopic expression of Msx2 in even-numbered rhombomeres induces apoptotic elimination of cranial neural crest cells in ovo. Development. 1998, 125: 1627-1635.PubMed

Wu LY, Li M, Hinton DR, Guo L, Jiang S, Wang JT, Zeng A, Xie JB, Snead M, Shuler C, Maxson RE, Liu YH: Microphthalmia resulting from MSX2-induced apoptosis in the optic vesicle. Invest Ophthalmol Vis Sci. 2003, 44: 2404-2412. 10.1167/iovs.02-0317.CrossRefPubMed

Satoh K, Ginsburg E, Vonderhaar BK: Msx-1 and Msx-2 in mammary gland development. J Mammary Gland Biol Neoplasia. 2004, 9: 195-205. 10.1023/B:JOMG.0000037162.84758.b5.CrossRefPubMed

Ma L, Golden S, Wu L, Maxson R: The molecular basis of Boston-type craniosynostosis: the Pro148-->His mutation in the N-terminal arm of the MSX2 homeodomain stabilizes DNA binding without altering nucleotide sequence preferences. Hum Mol Genet. 1996, 5: 1915-1920. 10.1093/hmg/5.12.1915.CrossRefPubMed

Wilkie AO, Tang Z, Elanko N, Walsh S, Twigg SR, Hurst JA, Wall SA, Chrzanowska KH, Maxson RE: Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification. Nat Genet. 2000, 24: 387-390. 10.1038/74224.CrossRefPubMed

10.

Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer. 2002, 2: 777-785. 10.1038/nrc907.CrossRefPubMed

11.

Lanigan F, O'Connor D, Martin F, Gallagher WM: Molecular links between mammary gland development and breast cancer. Cell Mol Life Sci. 2007, 64: 3159-3184. 10.1007/s00018-007-7386-2.CrossRefPubMed

12.

Humphreys RC, Krajewska M, Krnacik S, Jaeger R, Weiher H, Krajewski S, Reed JC, Rosen JM: Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development. 1996, 122: 4013-4022.PubMed

13.

McBryan J, Howlin J, Kenny PA, Shioda T, Martin F: ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene. 2007, 26: 6406-6419. 10.1038/sj.onc.1210468.CrossRefPubMed

14.

Satoh K, Hovey RC, Malewski T, Warri A, Goldhar AS, Ginsburg E, Saito K, Lydon JP, Vonderhaar BK: Progesterone enhances branching morphogenesis in the mouse mammary gland by increased expression of Msx2. Oncogene. 2007, 26: 7526-7534. 10.1038/sj.onc.1210555.CrossRefPubMed

15.

Malewski T, Milewicz T, Krzysiek J, Gregoraszczuk EL, Augustowska K: Regulation of Msx2 gene expression by steroid hormones in human nonmalignant and malignant breast cancer explants cultured in vitro. Cancer Invest. 2005, 23: 222-228. 10.1081/CNV-200055958.CrossRefPubMed

16.

di Bari MG, Ginsburg E, Plant J, Strizzi L, Salomon DS, Vonderhaar BK: Msx2 induces epithelial-mesenchymal transition in mouse mammary epithelial cells through upregulation of Cripto-1. J Cell Physiol. 2009, 219: 659-666. 10.1002/jcp.21712.CrossRefPubMedPubMedCentral

17.

Satoh K, Hamada S, Kimura K, Kanno A, Hirota M, Umino J, Fujibuchi W, Masamune A, Tanaka N, Miura K, Egawa S, Motoi F, Unno M, Vonderhaar BK, Shimosegawa T: Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells. Am J Pathol. 2008, 172: 926-939. 10.2353/ajpath.2008.070346.CrossRefPubMedPubMedCentral

18.

Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, Van Wijnen AJ, Young MF, Lian JB, Stein GS, Gerstenfeld LC: Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res. 2003, 63: 2631-2637.PubMed

19.

Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V: Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer. 1996, 69: 350-353. 10.1002/(SICI)1097-0215(19960822)69:4<350::AID-IJC19>3.0.CO;2-9.CrossRefPubMed

20.

Marazzi G, Wang Y, Sassoon D: Msx2 is a transcriptional regulator in the BMP4-mediated programmed cell death pathway. Dev Biol. 1997, 186: 127-138. 10.1006/dbio.1997.8576.CrossRefPubMed

21.

Gomes WA, Kessler JA: Msx-2 and p21 mediate the pro-apoptotic but not the anti-proliferative effects of BMP4 on cultured sympathetic neuroblasts. Dev Biol. 2001, 237: 212-221. 10.1006/dbio.2001.0344.CrossRefPubMed

22.

Israsena N, Kessler JA: Msx2 and p21(CIP1/WAF1) mediate the proapoptotic effects of bone morphogenetic protein-4 on ventricular zone progenitor cells. J Neurosci Res. 2002, 69: 803-809. 10.1002/jnr.10362.CrossRefPubMed

23.

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed

24.

Merck & Co., Inc: [http://www.rii.com]

25.

O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, Higgins DG, Jirstrom K, Landberg G, Gallagher WM: CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 2007, 120: 1434-1443. 10.1002/ijc.22413.CrossRefPubMedPubMedCentral

26.

Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K: Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008, 68: 9212-9220. 10.1158/0008-5472.CAN-08-1135.CrossRefPubMed

27.

Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin F, Duffy MJ, Gallagher WM: Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer. 2009, 124: 2088-2097. 10.1002/ijc.24159.CrossRefPubMed

28.

Hughes L, Malone C, Chumsri S, Burger AM, McDonnell S: Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis. 2008, 25: 549-557. 10.1007/s10585-008-9169-z.CrossRefPubMed

29.

Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K: Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol. 2008, 61: 197-203. 10.1136/jcp.2006.040378.CrossRefPubMed

30.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.CrossRefPubMed

31.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral

32.

Newberry EP, Latifi T, Towler DA: The RRM domain of MINT, a novel Msx2 binding protein, recognizes and regulates the rat osteocalcin promoter. Biochemistry. 1999, 38: 10678-10690. 10.1021/bi990967j.CrossRefPubMed

33.

Mebratu Y, Tesfaigzi Y: How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?. Cell Cycle. 2009, 8: 1168-1175. 10.4161/cc.8.8.8147.CrossRefPubMedPubMedCentral

34.

Brennan DJ, Rexhepaj E, O'Brien SL, McSherry E, O'Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM: Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res. 2008, 14: 2681-2689. 10.1158/1078-0432.CCR-07-1760.CrossRefPubMed

35.

Barnes DM, Gillett CE: Cyclin D1 in breast cancer. Breast Cancer Res Treat. 1998, 52: 1-15. 10.1023/A:1006103831990.CrossRefPubMed

36.

Bostrom P, Soderstrom M, Palokangas T, Vahlberg T, Collan Y, Carpen O, Hirsimaki P: Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes. 2009, 2: 140-10.1186/1756-0500-2-140.CrossRefPubMedPubMedCentral

37.

Sanchez-Pulido L, Rojas AM, van Wely KH, Martinez AC, Valencia A: SPOC: a widely distributed domain associated with cancer, apoptosis and transcription. BMC Bioinformatics. 2004, 5: 91-10.1186/1471-2105-5-91.CrossRefPubMedPubMedCentral

38.

Hiriart E, Gruffat H, Buisson M, Mikaelian I, Keppler S, Meresse P, Mercher T, Bernard OA, Sergeant A, Manet E: Interaction of the Epstein-Barr virus mRNA export factor EB2 with human Spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links Spen proteins with splicing regulation and mRNA export. J Biol Chem. 2005, 280: 36935-36945. 10.1074/jbc.M501725200.CrossRefPubMed

39.

Ma X, Renda MJ, Wang L, Cheng EC, Niu C, Morris SW, Chi AS, Krause DS: Rbm15 modulates Notch-induced transcriptional activation and affects myeloid differentiation. Mol Cell Biol. 2007, 27: 3056-3064. 10.1128/MCB.01339-06.CrossRefPubMedPubMedCentral

40.

Lindtner S, Zolotukhin AS, Uranishi H, Bear J, Kulkarni V, Smulevitch S, Samiotaki M, Panayotou G, Felber BK, Pavlakis GN: RNA-binding motif protein 15 binds to the RNA transport element RTE and provides a direct link to the NXF1 export pathway. J Biol Chem. 2006, 281: 36915-36928. 10.1074/jbc.M608745200.CrossRefPubMed

41.

Raffel GD, Mercher T, Shigematsu H, Williams IR, Cullen DE, Akashi K, Bernard OA, Gilliland DG: Ott1(Rbm15) has pleiotropic roles in hematopoietic development. Proc Natl Acad Sci USA. 2007, 104: 6001-6006. 10.1073/pnas.0609041104.CrossRefPubMedPubMedCentral

42.

TargetBreast: [http://www.targetbreast.com]

Title: Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro
Authors: Fiona Lanigan
Gabriela Gremel
Rowena Hughes
Donal J Brennan
Finian Martin
Karin Jirström
William M Gallagher
Publication date: 01-08-2010
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 4/2010
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2621

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2010

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells

BRCA1: linking HOX to breast cancer suppression

A prophylactic vaccine for breast cancer?

Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density

Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo

Columnar cell lesions and subsequent breast cancer risk: a nested case-control study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer